According to a new report LAMEA Biodefense Market, published by KBV research, the LAMEA Biodefense Market would witness market growth of 6.7% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Biodefense Market by Country in 2019, thereby, achieving a market value of $351.7 million by 2026. The Argentina market would witness a CAGR of 7.6% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 6.1% during (2020 - 2026).
The Anthrax market dominated the Saudi Arabia Biodefense Market by Product in 2019, growing at a CAGR of 5.7 % during the forecast period. The Smallpox market is estimated to grow at a CAGR of 6.1% during (2020 - 2026). Additionally, The Botulism market would showcase highest CAGR of 8.5% during (2020 - 2026).
The Marketing Asset Management market dominated the South Africa Biodefense Market by Solutions Type 2019, thereby, achieving a market value of $14.7 million by 2026. The Project Management market is showcasing a CAGR of 15.4% during (2020 - 2026). Additionally, The Brand & Advertisement Management market is experiencing a CAGR of 17% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/lamea-biodefense-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
By Product
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
